CDTX
Income statement / Annual
Last year (2023), Cidara Therapeutics, Inc.'s total revenue was $63.91 M,
a decrease of 0.60% from the previous year.
In 2023, Cidara Therapeutics, Inc.'s net income was -$22.93 M.
See Cidara Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$63.91 M
|
$64.29 M
|
$49.57 M
|
$12.07 M
|
$20.92 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.52 M |
$143,000.00 |
$189,000.00 |
$68.02 M |
$46.40 M |
$523,000.00 |
$667,000.00 |
$732,000.00 |
$461,000.00 |
$0.00 |
| Gross Profit |
$62.38 M |
$64.15 M |
$49.38 M |
-$55.95 M |
-$25.49 M |
-$523,000.00 |
-$667,000.00 |
-$732,000.00 |
-$461,000.00 |
$0.00 |
| Gross Profit Ratio |
0.98 |
1 |
1 |
-4.64 |
-1.22 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$68.53 M
|
$75.52 M
|
$73.09 M
|
$68.02 M
|
$46.40 M
|
$49.14 M
|
$42.82 M
|
$35.70 M
|
$23.48 M
|
$6.71 M
|
| General & Administrative
Expenses |
$18.33 M
|
$18.49 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
$3.31 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.33 M
|
$18.49 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
$3.31 M
|
| Other Expenses |
-$68.53 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$211,000.00 |
$0.00 |
$0.00 |
$0.00 |
-$183,000.00 |
| Operating Expenses |
$86.87 M |
$94.01 M |
$91.83 M |
$83.92 M |
$62.64 M |
$63.29 M |
$55.72 M |
$48.44 M |
$32.31 M |
$10.02 M |
| Cost And Expenses |
$88.39 M |
$94.01 M |
$91.83 M |
$83.92 M |
$62.64 M |
$63.29 M |
$55.72 M |
$48.44 M |
$32.31 M |
$10.02 M |
| Interest Income |
$2.00 M |
$191,000.00 |
$212,000.00 |
$262,000.00 |
$221,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$191,000.00 |
$212,000.00 |
-$262,000.00 |
$221,000.00 |
$629,000.00 |
-$7,000.00 |
$271,000.00 |
$120,000.00 |
$0.00 |
| Depreciation &
Amortization |
$118,000.00
|
$143,000.00
|
$189,000.00
|
$286,000.00
|
$328,000.00
|
$523,000.00
|
$667,000.00
|
$732,000.00
|
$461,000.00
|
$179,000.00
|
| EBITDA |
-$24.37 M
|
-$29.72 M
|
-$42.26 M
|
-$71.62 M
|
-$42.14 M
|
-$67.14 M
|
-$55.72 M
|
-$48.44 M
|
-$32.31 M
|
-$8.23 M
|
| EBITDA Ratio |
-0.38 |
-0.46 |
-0.85 |
-5.94 |
-2.01 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.38
|
-0.46
|
-0.85
|
-5.95
|
-1.99
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$2.00 M
|
$191,000.00
|
-$212,000.00
|
-$262,000.00
|
$632,000.00
|
$3.64 M
|
-$7,000.00
|
$271,000.00
|
$120,000.00
|
-$1.79 M
|
| Income Before Tax |
-$22.49 M |
-$29.53 M |
-$42.47 M |
-$72.11 M |
-$41.09 M |
-$59.02 M |
-$55.73 M |
-$48.17 M |
-$32.19 M |
-$11.89 M |
| Income Before Tax Ratio
|
-0.35
|
-0.46
|
-0.86
|
-5.98
|
-1.96
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$443,000.00 |
$272,000.00 |
$1.44 M |
$262,000.00 |
-$1.01 M |
$4.27 M |
-$667,000.00 |
-$732,000.00 |
-$461,000.00 |
$1.70 M |
| Net Income |
-$22.93 M |
-$29.80 M |
-$43.91 M |
-$72.37 M |
-$40.09 M |
-$59.02 M |
-$55.73 M |
-$48.17 M |
-$32.19 M |
-$11.89 M |
| Net Income Ratio |
-0.36 |
-0.46 |
-0.89 |
-6 |
-1.92 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-5.25 |
-8.53 |
-16.75 |
-34.83 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-64.9 |
-290.15 |
| EPS Diluted |
-5.25 |
-8.53 |
-16.74 |
-34.83 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-64.9 |
-290.15 |
| Weighted Average Shares
Out |
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875,043.00
|
$724,449.00
|
$496,018.00
|
$40,993.00
|
| Weighted Average Shares
Out Diluted |
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875,043.00
|
$724,449.00
|
$496,019.00
|
$40,993.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
